Khondrion and Medvisis Announce Exclusive Licensing Agreement to Commercialize a New Molecular Entity (NME) for Primary Mitochondrial Diseases in Switzerland and Liechtenstein

NIJMEGEN, the Netherlands & Haegendorf, Switzerland – August 18, 2025